A Randomized Phase II Trial of Sacituzumab Govitecan (SG) and Bevacizumab Versus Standard of Care Carboplatin, Pegylated Liposomal Doxorubicin (PLD) and Bevacizumab in Patients With Platinum-Sensitive Ovarian Cancer That Has Progressed on Prior Maintenance PARP Inhibitor Therapy

This phase II trial compares the effect of sacituzumab govitecan and bevacizumab to standard care (carboplatin, pegylated liposomal doxorubicin, and bevacizumab) in patients with ovarian cancer that has come back after an initial response to platinum therapy (platinum-sensitive), that has progressed after poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor maintenance therapy (recurrent), and that has a mutation in the BRCA1 or BRCA2 genes or is homologous recombination deficient. Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a drug called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as TROP2 receptors, and delivers govitecan to kill them. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Liposomal doxorubicin is a form of the anticancer drug doxorubicin that is contained inside very tiny, fat-like particles. Liposomal doxorubicin may have fewer side effects and work better than other forms of the drug. Giving sacituzumab govitecan and bevacizumab may kill more tumor cells than standard care (carboplatin, pegylated liposomal doxorubicin, and bevacizumab) in patients with recurrent platinum-sensitive ovarian cancers that have BRCA1/2 mutations or homologous recombination deficiency.

开始日期2026-09-10

申办/合作机构

National Cancer Institute

NCT07393555

/ Not yet recruiting临床2期IIT

A Randomized Phase II Study of Sacituzumab Govitecan Alone, Ivonescimab Alone, or Sacituzumab Govitecan and Ivonescimab in Participants With Previously-Treated Actionable Genomic Alteration Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

This phase II Expanded Lung-MAP treatment trial compares how well sacituzumab govitecan alone, ivonescimab alone, or sacituzumab govitecan in combination with ivonescimab works in treating patients with non-small cell lung cancer (NSCLC) that has come back after a period of improvement (recurrent) or is stage IV and has a change in at least 1 of these genes: ALK, EGFR, HER2 (ERBB2), MET, NTRK, RET, and ROS1. This type of gene change is called an actionable genomic alteration (AGA), which means certain treatments can target the change to fight the cancer. Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a toxic drug called SN-38. Sacituzumab govitecan is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of tumor cells, known as TROP2 receptors, and delivers SN-38 to kill them. Ivonescimab is a bispecific antibody that can bind to two different antigens at the same time. It binds to programmed cell death protein 1 (PD1), a protein found on the surface of T cells (a type of white blood cell) and vascular endothelial growth factor (VEGF), a protein found on the surface of tumor cells. Ivonescimab may strengthen the immune system and interfere with the ability of tumor cells to grow and spread. Giving a combination of sacituzumab govitecan and ivonescimab work better than either drug alone, and sacituzumab govitecan alone, ivonescimab alone, or sacituzumab govitecan and ivonescimab together may work better than standard treatments at shrinking NSCLC with an AGA.

开始日期2026-08-07

申办/合作机构

SWOG

[+1]

NCT07367178

/ Not yet recruiting临床2期

Phase II Study to Improve Sacituzumab Govitecan Tolerance With Atropine in Patients With Advanced Triple-Negative and Hormone Receptor-Positive/HER2-Negative Breast Cancer

The SATROPIN study is an international, multicenter, open-label, single-arm, phase II clinical trial to assess whether the use of prophylactic administration of atropine may prevent diarrhea in participants with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) or hormone receptor-positive/HER2-negative (HR(+)/HER2-) treated with sacituzumab govitecan.

开始日期2026-07-01

申办/合作机构

Medica Scientia Innovation Research SL

100 项与戈沙妥组单抗相关的临床结果

登录后查看更多信息

100 项与戈沙妥组单抗相关的转化医学

登录后查看更多信息

100 项与戈沙妥组单抗相关的专利（医药）

登录后查看更多信息

2,072

项与戈沙妥组单抗相关的文献（医药）

2026-04-21·CANCER INVESTIGATION

The Major Advances of the Year in Breast Cancer: A Point of View After the ASCO 2025 Annual Meeting

Article

作者: Ismaili, Nabil

At ASCO 2025, several practice-changing studies in breast cancer were presented. In HR+ early BC, the SOFT/TEXT 15-year update confirmed the benefit of ovarian suppression plus endocrine therapy, while OASIS-4 showed elinzanetant reduced endocrine-related vasomotor symptoms. In early TNBC, NRG-BR003 found no survival benefit from adding carboplatin. In HER2+ early breast cancer, omitting carboplatin preserved efficacy with better tolerability. In advanced disease, DESTINY-Breast09 established trastuzumab deruxtecan plus pertuzumab as superior first-line therapy. SERENA-6 and VERITAC-2 highlighted ESR1-targeted strategies, while ASCENT-04/KEYNOTE-D19 demonstrated sacituzumab govitecan plus pembrolizumab improved outcomes in PD-L1-positive advanced TNBC.

2026-04-20·BRITISH JOURNAL OF CANCER

Real-world use and survival outcomes of sacituzumab govitecan in metastatic triple-negative breast cancer and hormone receptor-positive/HER2-negative metastatic breast cancer

Article

作者: Haddy, Nadia ; Shaaban, Aya Elhusseiny ; Vignot, Stéphane ; Zureik, Mahmoud ; Jourdain, Hugo ; Desplas, David

Abstract:

Background:

Sacituzumab govitecan (SG) was granted early access in France as third-line therapy for metastatic triple-negative breast cancer (mTNBC) and hormone receptor-positive/HER2-negative (HR+/HER2–mBC) metastatic breast cancer. This nationwide cohort study assessed its real-world use and survival outcomes.

Methods:

Using the French National Health Data System, we included all patients initiating SG between July 1, 2021, and December 31, 2023, with follow-up until June 30, 2024. Patient demographics, comorbidities, and prior treatments were recorded. Overall survival (OS) and time to treatment discontinuation (TTD) were estimated by Kaplan-Meier methods, and multivariable Cox models identified OS prognostic factors.

Results:

3653 patients were included: 2527 mTNBC and 1,126 HR+/HER2– mBC, with median ages of 58 and 61.5 years. Median OS was 11.0 months (95%CI: 10.4–11.7) for mTNBC and 11.4 months (95% CI: 10.7–12.4) for HR+/HER2–mBC. One-year survival was 47% and 48% and median TTD of 4.3 and 3.5 months, respectively. Poorer OS was independently associated with inpatient SG initiation and liver/digestive metastases. In mTNBC, additional factors included brain metastases, respiratory disease, tobacco-related hospitalisation, multiple metastatic sites, and prior treatments.

Conclusion:

The study highlights SG’s clinical relevance and the challenge of translating trial efficacy into real-world outcomes, reinforcing the need for further investigation of tolerability in broader populations.

2026-04-15·CLINICAL CANCER RESEARCH

Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer

Article

作者: Rampa, Dileep Reddy ; Lee, Jangsoon ; Tsuchikama, Kyoji ; Seo, Minji ; Sridhar, Nithya ; Sledge, George W. ; Ueno, Naoto T. ; Ogata, Nanae ; Yang, Zhaoxuan ; Maynard, Jennifer A. ; Wannaphut, Chalothorn ; Fujii, Takeo

Abstract:

Purpose::

Antibody–drug conjugates (ADC) have transformed the treatment of breast cancer. FDA-approved ADC such as trastuzumab deruxtecan (T-DXd), sacituzumab govitecan (SG), and datopotamab deruxtecan (Dato-DXd) have demonstrated clinical benefit; however, drug resistance will almost inevitably emerge in the metastatic setting, and there is no established strategy for selecting subsequent ADC after disease progression following the first exposure to the ADC. This study aimed to define mechanisms of acquired resistance and evaluate rational sequencing approaches.

Experimental Design::

We generated breast cancer cell lines resistant to T-DXd (TDXd-R) and SG (SG-R). We assessed antigen expression, internalization, and resistance pathways, including efflux transporter activity. To identify therapeutic strategies, we tested the efficacy of ADC carrying non–topoisomerase I (Topo1) payloads in in vitro and in vivo models.

Results::

Resistance in both TDXd-R and SG-R models was primarily mediated by payload-specific factors, notably upregulation of efflux transporters, rather than loss of antigen expression. Switching to ADC with mechanistically different payloads, including microtubule inhibitors, restored antitumor activity in vitro and in vivo.

Conclusions::

Cross-resistance to sequential ADC is primarily driven by shared payload mechanisms rather than loss of the target. Our data also suggest that the clinical benefit of sequential Topo1-based ADC may be reduced following disease progression on a Topo1-based ADC, likely due to these shared resistance pathways. Importantly, switching to ADC with non–cross-resistant payload classes may offer a more effective approach to guide ADC sequencing in patients with metastatic breast cancer, supporting payload diversification as a clinically actionable strategy.

2,090

项与戈沙妥组单抗相关的新闻（医药）

2026-04-30

·ioncology

瞭望前瞻丨2026 ESMO BC盛幕将启，一文汇总重磅研究进展

编者按：2026年欧洲肿瘤内科学会乳腺癌年会（ESMO BC）将于当地时间5月6日至8日在德国柏林举行。本次大会内容丰富、亮点纷呈，全面覆盖乳腺癌的靶向治疗、内分泌治疗以及免疫治疗等领域，届时将有多项极具影响力的研究成果公布。《肿瘤瞭望-乳腺时讯》特别对会议即将披露的重要研究内容进行了系统汇总，以飨读者。 Proffered Paper session 1 时间：5月6日16:00 - 17:30 地点：Berlin Hall 主席：Sara M. Tolaney (Boston, MA, United States of America) Masakazu Toi (Bunkyo-ku, Japan) LBA1-Residual cancer burden (RCB) following neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (ddAC-THP) in high-risk HER2+ early-stage breast cancer (eBC) 高危HER2+早期乳腺癌（eBC）新辅助治疗（NAT）后T-DXd序贯紫杉醇+曲妥珠单抗+帕妥珠单抗（THP）与剂量密集多柔比星+环磷酰胺序贯THP（ddAC-THP）的残余肿瘤负荷（RCB）比较报告时间：16:00 - 16:10 讲者：Lajos Pusztai (New Haven, CT, United States of America) 214O - Chemotherapy-free, pathological complete response (pCR)-guided strategy with trastuzumab-pertuzumab (HP) and T-DM1 in HER2+ early breast cancer (EBC): PHERGain-2 曲妥珠单抗-帕妥珠单抗（HP）和T-DM1治疗HER2+早期乳腺癌（EBC）的无化疗、病理完全缓解（pCR）指导策略：PHERGain-2 报告时间：16:10 - 16:20 讲者：Antonio LLOMBART CUSSAC (Valencia, Spain) 215O - Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine for triple-negative breast cancer (TNBC) with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21) 一项随机 II 期试验，旨在评估阿替利珠单抗联合卡培他滨辅助治疗对比卡培他滨单药治疗新辅助化疗后残留浸润性癌的三阴性乳腺癌 (TNBC) 的疗效和安全性（MIRINAE 试验，KCSG-BR18-21）报告时间：16:20 - 16:30 讲者：In Hae Park (Seoul, Republic of Korea) 1O - ctDNA detection rates during surveillance in high-risk HR+/HER2 negative breast cancer from the TRAK-ER study TRAK-ER研究中高危HR+/HER2阴性乳腺癌监测期间ctDNA的检出率报告时间：16:52 - 17:02 讲者：Niamh Cunningham (London, United Kingdom) LBA2 - A window-of-opportunity (WOO) trial of giredestrant +/- LHRH analogue vs anastrozole + LHRHa in premenopausal patients with ER+/HER2- early breast cancer: PREcoopERA 一项在ER+/HER2-早期乳腺癌绝经前患者中评估giredestrant±LHRH类似物对比阿那曲唑+LHRH类似物的机会窗（WOO）试验：PREcoopERA 报告时间：17:02 - 17:12 讲者：Elisabetta Munzone (Milan, Italy) Rapid Oral session 1 时间：5月7日08:30 - 10:00 地点：Berlin Hall 主席：Sonia Pernas (Hospitalet de Llobregat, Spain) Peter Dubsky (Luzern, Switzerland) 216RO - 5-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in HER2[+] early breast cancer (EBC) patients (pts) 基于策略的随机Ⅱ期PHERGain试验评估 HER2+早期乳腺癌（EBC）患者化疗（CT）降阶治疗的5年无侵袭性疾病生存期（iDFS）报告时间：08:30 - 08:35 讲者：Javier C. Cortés (Barcelona, Spain) 217RO - Neoadjuvant trastuzumab, pertuzumab and tucatinib without chemotherapy in HER2+ early breast cancer: The TRAIN-4 study 新辅助曲妥珠单抗、帕妥珠单抗联合图卡替尼治疗HER2阳性早期乳腺癌，无需化疗：TRAIN-4研究报告时间：08:35 - 08:40 讲者：Fleur M. Louis (Amsterdam, Netherlands) 2RO - Tumor-informed ctDNA dynamics and efficacy of sequential pyrotinib–pertuzumab neoadjuvant therapy in HER2-positive breast cancer: A randomized, open-label, phase II trial 肿瘤相关ctDNA动态变化及序贯吡咯替尼-帕妥珠单抗新辅助治疗在HER2阳性乳腺癌中的疗效：一项随机、开放标签的II期试验报告时间：08:40 - 08:45 讲者：Haoyu Wang (上海交通大学医学院附属瑞金医院) 3RO - Improved identification of high-risk node-negative breast cancer using a multimodal clinical, pathologic, and genomic model in the TAILORx Trial 在TAILORx试验中，利用多模态临床、病理和基因组模型改进了高危淋巴结阴性乳腺癌的识别报告时间：09:00 - 09:05 讲者：Frederick M. Howard (Chicago, IL, United States of America) 218RO - Revisiting estrogen receptor positivity in breast cancer: Long-term outcomes and endocrine therapy benefit across ER expression levels 重新审视乳腺癌中雌激素受体阳性亚型：不同雌激素受体表达水平下的长期预后和内分泌治疗获益报告时间：09:05 - 09:10 讲者：Flora Nguyen Van Long (Quebec, QC, Canada) 187RO - Lymph node surgery and CDK4/6 inhibitors in early breast cancer: A cost-consequence analysis from 5 randomized trials 早期乳腺癌淋巴结手术和CDK4/6抑制剂：来自5项随机试验的成本效益分析报告时间：09:10 - 09:15 讲者：Andre Pfob (Heidelberg, Germany) 4RO - A comparative analysis between tissue-free ctDNA detection and a multivariant tumour-informed assay in early triple-negative breast cancer 早期三阴性乳腺癌中无组织ctDNA检测与多变量肿瘤信息检测的比较分析报告时间：09:15 - 09:20 讲者：Niamh Cunningham (London, United Kingdom) LBA3 - The UK retrospective genetic testing programme: Utilising linkage of nationally collected data to identify and offer germline genetic testing to patients with historic diagnoses of breast or ovarian cancer 英国回顾性基因检测计划：利用国家收集的数据的链接来确定和提供生殖细胞系基因检测给有乳腺癌或卵巢癌病史的患者报告时间：09:44 - 09:49 讲者：Clare A. Turnbull (London, United Kingdom) LBA5 - Efficacy of an mHealth intervention to address informational needs in adolescent and young adult (AYA) breast cancer survivors (BCS): A secondary outcome from the YES trial 移动医疗干预对满足青少年和年轻成人（AYA）乳腺癌幸存者（BCS）信息需求的效果：YES试验的次要结局报告时间：09:54 - 09:59 讲者：Shoshana M. Rosenberg (New York, NY, United States of America) Proffered Paper session 2 时间：5月7日14:15 - 15:45 地点：Berlin Hall 主席：Nicholas C. Turner (London, United Kingdom) 418O - Safety and patient (pt)-reported outcomes (PROs) from evERA breast cancer (BC): A phase III trial of giredestrant (GIRE) + everolimus (E) in pts with oestrogen receptor-positive, HER2-negative advanced BC (ER+, HER2– aBC) previously treated with a CDK4/6 inhibitor (i) evERA BC研究的安全性和患者报告结局（PRO）：一项III期试验，评估giredestrant+依维莫司在既往接受过CDK4/6抑制剂治疗的雌激素受体阳性、HER2 阴性晚期乳腺癌（ER+, HER2– aBC）) 患者中的疗效报告时间：14:15 - 14:25 讲者：Miguel Martin (Madrid, Spain) 415O - First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in patients (pts) with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Patient-reported outcomes (PROs) from TROPION-Breast02 在不能接受免疫治疗的局部复发、不可手术或转移性三阴性乳腺癌（mTNBC）患者（pts）中，一线（1L）datopotamab deruxtecan（Dato-DXd）与化疗（CT）的比较：TROPION-Breast02研究的患者报告结局（PRO）报告时间：14:25 - 14:35 讲者：Peter Schmid (London, United Kingdom) 416O - SMART: On-treatment ctDNA dynamics predicts response and progression in metastatic breast cancer SMART：治疗期间ctDNA动态变化可预测转移性乳腺癌的疗效和进展报告时间：14:53 - 15:03 讲者：Pedram Razavi (New York, NY, United States of America) 417O - Capivasertib (C) and fulvestrant (F) for patients (pts) with HR+/HER2− advanced breast cancer (ABC): Final overall survival (OS) results from the phase III CAPItello-291 trial 卡匹色替联合氟维司群用于HR+/HER2-晚期乳腺癌（ABC）患者：III期CAPItello-291试验的最终总生存期（OS）结果报告时间：15:03 - 15:13 讲者：Hope S. Rugo (Los Angeles, CA, United States of America) Rapid Oral session 2 时间：5月8日08:30 - 10:00 地点：Berlin Hall 419RO - Emergence of ESR1 mutations (ESR1m) in ctDNA during first-line (1L) endocrine-based therapy in HR+/HER2- advanced breast cancer: Findings from the SERENA-6 trial 在HR+/HER2-晚期乳腺癌一线内分泌治疗期间，ctDNA中ESR1突变（ESR1m）的出现情况：SERENA-6试验的结果报告时间：08:30 - 08:35 讲者：François Clément Bidard (Paris, France) 420RO - Efficacy of inavolisib (INAVO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC) with and without hyperglycaemia (HG) in the phase III INAVO120 trial 在III期INAVO120试验中，评估伊利那塞+哌柏西利+氟维司群联合治疗PIK3CA突变、激素受体阳性、HER2阴性、内分泌耐药的晚期乳腺癌（aBC）患者（伴或不伴高血糖）的疗效报告时间：08:35 - 08:40 讲者：Sibylle Loibl (Neu-Isenburg, Germany) 421RO - Dose optimization of BTX-9341, a first-in-class CDK4/6 bifunctional degrader, in CDK4/6 inhibitor-pretreated HR+/HER2− advanced/metastatic breast cancer 在接受过CDK4/6抑制剂治疗的HR+/HER2-晚期/转移性乳腺癌患者中，BTX-9341（一种首创的CDK4/6双功能降解剂）的剂量优化报告时间：08:40 - 08:45 讲者：Matthew P. Goetz (Rochester, NY, United States of America) 422RO - A phase II study of patritumab deruxtecan (HER3-DXd) in patients (pts) with metastatic breast cancer (MBC) Patritumab Deruxtecan（HER3-DXd）治疗转移性乳腺癌（MBC）患者的II期研究报告时间：09:00 - 09:05 讲者：Erika P. Hamilton (Nashville, TN, United States of America) LBA4 - Efficacy and safety of sacituzumab govitecan (SG) plus trastuzumab in patients with HER2+ metastatic breast cancer after prior trastuzumab deruxtecan (T-DXd): Results from the phase II SATEEN trial sacituzumab govitecan（SG）联合曲妥珠单抗治疗既往接受过T-DXd治疗的HER2+转移性乳腺癌患者的疗效和安全性：2期SATEEN试验的结果报告时间：09:10 - 09:15 讲者：Paolo Tarantino (Boston, MA, United States of America) 423RO - Addition of tucatinib to trastuzumab emtansine (T-DM1) in patients with previously treated HER2+ locally advanced/metastatic breast cancer (LA/MBC): Updated efficacy analysis from the HER2CLIMB-02 trial 在既往接受过治疗的HER2阳性局部晚期/转移性乳腺癌 (LA/MBC) 患者中，T-DM1联合图卡替尼治疗方案的疗效：HER2CLIMB-02 试验的最新疗效分析报告时间：09:15 - 09:20 讲者：Giuseppe Curigliano (Milan, Italy) 424RO - SACI-IO HR+: Final results from a randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) SACI-IO HR+：一项随机 II 期试验的最终结果，该试验评估了戈沙妥珠单抗联合或不联合帕博利珠单抗治疗激素受体阳性/HER2阴性 (HR+/HER2-) 转移性乳腺癌 (MBC)的疗效报告时间：09:35 - 09:40 讲者：Ana C. Garrido-Castro (Boston, MA, United States of America) 425RO - A randomized phase II study of pembrolizumab plus carboplatin vs. carboplatin alone in unresectable advanced breast cancer (ABC) with chest wall disease (CWD) [ICI-CHEST, TBCRC 44] 一项随机II期研究比较了帕博利珠单抗联合卡铂与单用卡铂治疗不可切除的晚期乳腺癌（ABC）伴胸壁疾病（CWD）的疗效 [ICI-CHEST, TBCRC 44] 报告时间：09:40 - 09:45 讲者：Neelima Vidula (Boston, MA, United States of America) 426RO - Pumitamig in combination with DB-1305/BNT325 as first-line (1L) treatment for patients with advanced or metastatic triple-negative breast cancer (a/mTNBC): Efficacy and safety from a multicenter, open-label, phase I/II trial Pumitamig联合DB-1305/BNT325作为一线（1L）治疗晚期或转移性三阴性乳腺癌（a/mTNBC）患者的疗效和安全性：一项多中心、开放标签的1/2期试验报告时间：09:45 - 09:50 讲者：张剑（复旦大学附属肿瘤医院）（来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床结果临床2期免疫疗法

2026-04-29

·CPA老张的ESG账簿

跌落神坛的AAA级巨头：吉利德的ESG账本里，藏着多少出海药企的“致命坑”？

之前在咱们《CPA老张的ESG账簿》里，陆续拆解过快而精医药、爱德华兹生命科学的器械逻辑，也盘过药明康德的CXO出海风波，以及华东医药的本土转型。今天，轮到了一家市值常年盘踞全球Top梯队、在整个泛生物医疗行业绝对绕不开的巨头——吉利德科学（Gilead Sciences, Inc.，纳斯达克代码：GILD）。就在前两天（2026年4月27日），MSCI更新了吉利德的ESG评级。让人有些意外的是，这家原本稳居AAA级“神坛”的优等生，这次被下调到了AA级。具体得分上：环境（E）6.94分，社会（S）4.99分，治理（G）5.9分。对于一家年营收逼近300亿美元级别、掌控着全球HIV和丙肝治疗命脉的跨国大厂来说，评级下调绝对不是因为填错了几张表，而是其底层的商业模式与愈发严苛的ESG评价体系产生了硬碰撞。今天，咱们就用财会审税的实操视角，翻一翻吉利德2024-2025年的最新底稿，看看这个AA级背后，到底藏着哪些“好账”与“坏账”。01 财报透视：医药界“印钞机”的底盘与隐忧在深入评估一家企业的ESG表现之前，必须先摸清它的财务与业务基本盘。脱离了商业实质谈社会责任，都是空中楼阁。成立于1987年、总部位于美国加州福斯特城的吉利德，是典型的“精准狙击手”。它的核心业务聚焦在HIV、病毒性肝炎、COVID-19以及肿瘤和炎症领域。在过去十几年里，它不仅研发出了治愈丙肝的特效药（如Epclusa和Harvoni），更在抗艾滋病（HIV）领域占据了统治地位。翻开其最新的财报数据，这台“印钞机”的运转依然强悍，但也经历了剧烈的业绩波动：营收与利润的反弹：2024年，由于其肿瘤药物Trodelvy在非小细胞肺癌（NSCLC）三期临床试验中的失利，吉利德极其果断地计提了高达42亿美元的研发资产减值（IPR&D impairment）。这一“财务洗澡”直接导致2024年净利润骤降至4.8亿美元。但到了2025年，轻装上阵的吉利德实现总营收294.43亿美元（同比增长2%），净利润强势反弹至85.1亿美元。王牌管线的突破：2025年，其HIV产品线贡献了207.52亿美元的营收。其中，Biktarvy（必妥维）单品营收高达143.34亿美元。更具历史意义的是，2025年FDA正式批准了其首个一年两次的HIV预防（PrEP）注射剂Yeztugo（lenacapavir）。这款药物被《科学》杂志评为2024年度突破，极大地改变了公共卫生预防的规则。隐忧与挑战：由现年61岁的董事长兼CEO Daniel P. O'Day领衔的管理层，目前正面临着切实的压力。一方面是政策端，美国《通胀削减法案》（IRA）对Medicare定价的干预，以及340B折扣项目的持续影响，正在挤压其利润空间。另一方面是残酷的专利悬崖，虽然近期通过和解将Biktarvy在美国的仿制药推迟到了2036年，但在Kite Pharma主导的细胞疗法（Yescarta、Tecartus）领域，2025年销售额因竞争加剧而下降了7%。这种高压的商业环境，不可避免地会深刻影响其ESG的战略选择。02 环境（E）的底气：6.94分背后的“教科书操作” 在这次MSCI评分中，吉利德的环境（E）维度拿到了6.94的高分。对于普遍高耗能的生物制药行业来说，这个分数极具含金量。翻阅其报告，这并非依赖买碳汇指标粉饰，而是真正落到了实处。 1. 能源转型与运营脱钩2025年，吉利德正式宣布实现了其运营端100%使用可再生电力（Renewable Electricity）的目标。更让审计人看重的一个数据是：从2019年到2025年，吉利德全球设施总面积增长了17%，但绝对能耗反而下降了7%。在财务逻辑里，这叫真正的“规模扩张与碳排放脱钩”。其位于加州福斯特城的总部甚至拿下了TRUE（资源使用效率）金级零废弃认证。 2. 直面最难啃的骨头：Scope 3管理制药企业最大的环境压力不在自家车间，而在上下游供应链。报告坦承，范围3（Scope 3）的间接排放占了吉利德总碳足迹的93%。为了啃下这块硬骨头，吉利德对供应商进行了严格的筛查：在其占Scope 3排放前75%的核心供应商中，已有62%设定或承诺了SBTi（科学碳目标倡议）对齐的减排目标，55%已经获得了SBTi的正式批准。这种对供应链碳数据的穿透管理能力，是其维持高分的关键。 3. 水资源与塑料的减法水资源消耗是药企的另一大痛点。吉利德设定了到2030年将自有设施的饮用水使用量减少30%的量化目标。此外，在非制造和非研发运营领域，其也全面推进了淘汰一次性塑料的计划。03 账本里的“坏账”：S维度4.99分的致命博弈相比于优秀的E，吉利德这次在社会（S）维度仅拿到4.99分，严重拖了后腿。这恰恰击中了跨国原研药企在ESG评估中最难平衡的“生死线”。对于医药企业，S维度的核心权重指标是医疗可及性（Access to Healthcare）。吉利德在这个问题上，展现出了极端的“割裂感”。一方面，它是惠及发展中国家的“公益标杆”。早在Yeztugo（lenacapavir）获批之前，吉利德就在2024年做出了史无前例的决定：与6家仿制药商签署免版税的自愿许可协议（Voluntary Licensing），覆盖120个高发病率、资源受限的中低收入国家。到了2025年，该药不仅在获批后数小时内发货，更与美国国务院（通过PEPFAR）和全球基金合作，承诺在三年内为多达300万人提供零利润的药物供应，直至仿制药产能跟上。这种将新药在同一年内推向美国和低收入国家的执行力，在制药史上是罕见的。此外，其FOCUS项目自2010年以来已支持完成了超过2470万次血液传播病毒测试。另一方面，它是欧美核心利润区备受抨击的“天价药主”。问题来了，既然在穷国这么慷慨，为什么S得分这么低？因为ESG评级不仅看你捐了多少，更看你在核心市场的定价伦理。创新药的研发成本极高，2025年吉利德的研发费用约为58亿美元。为了回本并赚取高额利润，其在欧美市场的定价极为高昂。在MSCI的模型中，这种巨大的定价落差、以及因此引发的公共卫生组织的抨击、抗议和潜在的政府审查，会被量化为“产品定价争议”负面事件。无论你在非洲做了多少零利润供药，只要在核心市场被认定存在“限制获取”或“定价过高”的争议风险，S维度就会被无情扣分。这是所有依赖专利垄断的创新药企必须面对的死结。04 治理（G）5.9分：合规背后的政策博弈治理维度5.9分，处于行业中游水平。吉利德在内部风控上做得很到位，比如设立了企业责任委员会（Corporate Responsibility Committee），由执行副总裁兼总法律顾问牵头，并且CFO是可持续发展计划的执行倡导者，确保ESG与财务规划和风险管理深度绑定。但影响其G得分向上的天花板，主要有两个因素：高管双重角色（Duality）：当前董事长与CEO均由Daniel P. O'Day一人担任。在国际主流的ESG治理评价中，董事会独立性是核心考量，职权过度集中通常会被视为潜在的治理瑕疵。政策游说与反垄断压力：在面对美国《通胀削减法案》（IRA）的药价谈判压力时，大型药企为了维护自身利益，往往会投入巨资进行政策游说（Lobbying）。虽然这是合法的商业防御，但在部分严苛的ESG评级标准下，这种试图干预药价调控的游说行为，往往会影响其在“反竞争行为”或“商业伦理”上的得分。05 跨界对标：给国内药企出海的实操启示将吉利德的ESG底稿摊开，对比我们国内的医药企业，差异是全方位的战略降维打击。与药明康德（CXO）对比：CXO作为“代工厂”和研发服务方，其ESG的核心痛点在于客户数据安全、动物福利和自身生产过程的碳排放。而吉利德作为拥有终端定价权的“品牌方”，其承受的火力集中在“药物可及性”和“专利伦理”上。国内创新药企（如百济神州、恒瑞）在产品出海时，必须明白你们面临的ESG审查将从“环保达标”直接升级为“商业道德审查”。与华东医药（传统制药+医美）对比：传统药企在向创新转型期，ESG报告更多体现的是末端环保技改和员工关怀。而吉利德已经把ESG做成了战略级的“护城河”——通过自愿许可协议对冲地缘政治与道德压力，通过SBTi目标倒逼供应链优化。06 深度评论：理中客视角下的ESG与商业逻辑最后，作为财务人，我们到底该怎么看待吉利德从AAA到AA的评级下滑？从实质重于形式的原则来看，评级下调并不意味着吉利德的基本面垮塌了，而是评价尺度的收紧和制药行业固有矛盾的显现。对资本市场和量化投资而言，高E和高S得分有时候意味着企业承担了过多的社会让利成本，短期内可能会压制ROE（净资产收益率）。吉利德的AA评级，恰恰给我们提供了一个完美的真实样本：在现实的商业世界里，不存在完美的ESG圣人。企业必须在研发巨额投入的“回本诉求”与全球公共卫生的“普惠需求”之间走钢丝。对于正在疯狂出海的中国药企而言，吉利德的账本带来了最冷酷的忠告：出海欧美，我们不能光盯着FDA的获批信和高昂的定价。欧美市场对“药品定价伦理”和“供应链合规”的ESG审查，是一把悬在头顶的达摩克利斯之剑。如果你没有提前准备好类似于吉利德“分层定价（Tiered Pricing）”或“全球可及性方案”的战略对冲，一旦遭遇NGO的狙击或政策法案的绞杀，高昂的定价极容易在S维度引发灾难性的声誉和市场反噬。 ESG从来不是写在报告里的排版贴纸，它是企业用来穿越政策周期、降低全球化经营摩擦的终极风控工具。看懂了吉利德这本账，中国药企的出海之路，才能走得更稳、更远。

2026-04-29

·医脉通

“戈”破困局·生存获益 | 二线治疗优选：戈沙妥珠单抗为mTNBC中带来显著生存获益

引言三阴性乳腺癌（TNBC）由于缺乏有效的治疗靶点，靶向治疗选择有限，以化疗为主要治疗手段，生存获益不佳。尤其是一线治疗进展的晚期TNBC（mTNBC）患者，患者预后极差，临床亟需一种新型的治疗方案，以突破疗效瓶颈、改善患者长期生存。近年来，抗体偶联药物（ADC）快速发展，为mTNBC患者带来了新的希望。戈沙妥珠单抗（SG）作为全球首个靶向Trop-2的ADC药物，凭借III期ASCENT研究的突破性数据已成为mTNBC二线治疗优选。基于此，本文将结合mTNBC的诊疗现状，深度解析ASCENT研究的主要结果，明确SG的临床应用价值，为临床决策提供循证依据。 mTNBC治疗困境一线进展后治疗选择匮乏，生存获益亟待突破 TNBC约占所有乳腺癌的15%～20%，具有疾病进展快、侵袭性强、易复发转移的特点。超过1/3的TNBC患者会发生复发或远处转移，复发或转移性TNBC通常预后较差，5年生存率不足15%[1]。由于雌激素受体（ER）、孕激素受体（PR）和HER2均呈阴性，mTNBC对内分泌治疗及传统抗HER2靶向治疗不敏感，治疗手段仍以化疗为主[1,2]。目前，对于既往接受过治疗的mTNBC患者，单药化疗仍是其标准方案。然而研究显示，单药化疗的疗效有限，患者的疾病缓解率较低，无进展生存期（PFS）较短[3]。因此，临床亟需一种高效的新型治疗策略以突破当前治疗瓶颈，改善患者长期生存。近年来，随着研究的深入，新型ADC药物不断涌现，mTNBC的治疗迎来了新选择。Trop-2是一种跨膜钙信号转导蛋白，在包括乳腺癌（>90%）在内的多个肿瘤类型中高表达，是mTNBC领域研究的热门靶点[3]。SG是全球首个获批的Trop-2 ADC药物，III期ASCENT研究显示，其可为既往化疗经治的mTNBC患者带来显著生存获益，为该人群带来了新的希望[3]。 ASCENT研究 SG显著提升PFS与OS，为mTNBC患者带来全新治疗选择 ASCENT研究是一项国际、多中心、随机、对照III期临床试验，入组了529例既往接受过至少2种标准化疗（至少1种用于晚期阶段）的mTNBC患者，旨在比较SG与医生选择化疗（TPC）在该人群中的疗效与安全性。该研究的主要研究终点是独立影像评估（RECIST 1.1标准）的基线无脑转移患者的PFS。次要研究终点包括总生存期（OS）、客观缓解率（ORR）和安全性[3]。在PFS方面，SG在基线无脑转移人群和ITT人群中的表现均较TPC组显著更优，且在不同亚组人群中观察到一致的PFS获益。结果显示，在基线无脑转移人群中，SG组的中位PFS为5.6个月，显著高于TPC组的1.7个月（HR=0.39，P＜0.0001）[4]。在ITT人群中，SG组的中位PFS达4.8个月，同样显著高于TPC组的1.7个月（HR=0.43）。亚组分析显示，无论患者年龄是否≥65岁、既往化疗线数是否＞3线、是否接受过PD-1/PD-L1抑制剂治疗、是否初诊为TNBC患者、是否存在肝转移，SG组的中位PFS均优于TPC组，表明SG的疗效不受以上因素影响，能够为更广泛的mTNBC患者带来一致生存获益[3]。图1 基线无脑转移人群的PFS[4] 图2 ITT人群的PFS[3] 图3 亚组人群PFS分析[3] 在OS方面，SG同样在基线无脑转移人群和ITT人群中展现出显著优于TPC组的疗效。最终分析显示，在基线无脑转移人群中，SG组中位OS达12.1个月，较TPC组的6.7个月显著延长（HR=0.48；P＜0.0001）；在ITT人群中，SG治疗组的中位OS为11.8个月，同样显著长于TPC组的6.9个月（HR=0.51；P＜0.0001）[4]。另外，SG在ORR、缓解持续时间（DOR）等方面也表现出显著优势。在基线无脑转移的患者中，SG组的ORR达35%，而TPC组仅为5%。SG组的中位DOR为6.3个月，高于TPC组的3.6个月（HR=0.39），进一步验证了其良好的抗肿瘤活性[3]。 SG不但为TNBC患者带来了显著生存获益，同时还展现出可控的安全性。ASCENT研究中，SG组常见的治疗相关不良事件（TEAE）与既往分析结果一致，未出现新的安全信号。SG组最常见的≥3级TEAE为中性粒细胞减少症、白细胞减少症、腹泻、贫血等。在SG组中，治疗相关的任何级别皮疹（9%；其中1例为3级事件）和眼部毒性（5%；无>1级事件）发生率较低，且未观察到>2级的神经病变。SG组和TPC组因TEAE导致的停药率均较低（≤5%）。两组各有3例患者因AE死亡，均判定与SG治疗无关[3]。SG治疗相关的中性粒细胞减少症和腹泻可通过对症治疗进行管理[3]。临床价值凸显 SG重塑mTNBC二线治疗格局，开启ADC治疗新时代 ASCENT研究是mTNBC治疗领域的里程碑式研究，该研究证实SG可为经治mTNBC患者带来显著生存获益，打破了mTNBC二线及后线治疗仅依赖化疗的僵局，为该人群提供了一种新型高效治疗方案。同时，ASCENT研究的成功也为后续Trop-2 ADC药物在mTNBC领域中的研发和应用提供了参考。目前，SG已获得中国国家药品监督管理局（NMPA）批准，用于治疗既往至少接受过2种系统治疗（其中至少1种治疗针对转移性疾病）的不可切除的局部晚期或转移性三阴性乳腺癌成人患者[5]，且被国内外权威指南一致推荐作为mTNBC二线治疗优选方案[6,7]。SG凭借突破性的疗效与可控安全性，改变了mTNBC二线及后线治疗格局，为患者带来了全新的治疗选择。未来，随着SG等ADC药物的不断探索，mTNBC的诊疗策略将进一步优化，为更多mTNBC患者带来长期生存获益。参考文献 1.中国抗癌协会乳腺癌专业委员会, 中国抗癌协会国际医疗交流分会, 中国医师协会肿瘤医师分会乳腺癌学组. 中国晚期三阴性乳腺癌临床诊疗指南（2024版）[J]. 中华肿瘤杂志, 2024, 46(06): 471-480. 2.肖玉铃,等.三阴性乳腺癌精准治疗研究的新进展与未来展望[J].中国癌症杂志,2022,32(8):668-679. 3.Bardia A, Hurvitz S A, Tolaney S M, et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer[J]. The New England Journal of Medicine, 2021, 384(16): 1529-1541. 4.Bardia A, et al. 2022 ASCO. Poster 1071 5.注射用戈沙妥珠单抗说明书 6.《NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Breast Cancer. Version 1. 2026》 7.《中国抗癌协会中华医学会肿瘤学分会乳腺癌诊治指南与规范（2026年版精要本）》审批编号：CN-TRO-0390 有效期至：2027年12月31日撰写：ICEY 审校：Elan 排版：Atai 执行：Atai 本平台旨在为医疗卫生专业人士传递更多医学信息。本平台发布的内容，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。如该等信息被用于了解医学信息以外的目的，本平台不承担相关责任。本平台对发布的内容，并不代表同意其描述和观点。若涉及版权问题，烦请权利人与我们联系，我们将尽快处理。

100 项与戈沙妥组单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	戈沙妥组单抗	L01	DB12893

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
转移性三阴性乳腺癌	欧盟	Gilead Sciences Ireland UC	2021-11-22
转移性三阴性乳腺癌	冰岛	Gilead Sciences Ireland UC	2021-11-22
转移性三阴性乳腺癌	列支敦士登	Gilead Sciences Ireland UC	2021-11-22
转移性三阴性乳腺癌	挪威	Gilead Sciences Ireland UC	2021-11-22
乳腺癌	瑞士	Gilead Sciences, Inc.	2021-09-09
HR阳性/HER2阴性乳腺癌	澳大利亚	Gilead Sciences Pty Ltd.	2021-09-06
尿路上皮癌	美国	Gilead Sciences, Inc.	2021-04-13
三阴性乳腺癌	美国	Gilead Sciences, Inc.	2020-04-22

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
转移性乳腺癌	申请上市	中国	云顶药业（苏州）有限公司	2021-05-17
广泛期小细胞肺癌	临床3期	美国	Gilead Sciences, Inc.	2025-04-04
广泛期小细胞肺癌	临床3期	中国	Gilead Sciences, Inc.	2025-04-04
广泛期小细胞肺癌	临床3期	日本	Gilead Sciences, Inc.	2025-04-04
广泛期小细胞肺癌	临床3期	阿根廷	Gilead Sciences, Inc.	2025-04-04
广泛期小细胞肺癌	临床3期	澳大利亚	Gilead Sciences, Inc.	2025-04-04
广泛期小细胞肺癌	临床3期	比利时	Gilead Sciences, Inc.	2025-04-04
广泛期小细胞肺癌	临床3期	巴西	Gilead Sciences, Inc.	2025-04-04
广泛期小细胞肺癌	临床3期	加拿大	Gilead Sciences, Inc.	2025-04-04
广泛期小细胞肺癌	临床3期	法国	Gilead Sciences, Inc.	2025-04-04

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05581589 (CTgov)	临床2期	非肌层浸润性膀胱尿路上皮癌 \| 肌层浸润性膀胱癌	4	Radical Cystectomy+Sacituzumab Govitecan	遞範蓋鹹糧廠顧糧鑰遞 = 鹹襯鏇夢範積觸膚繭鏇餘鬱襯製襯憲憲蓋觸積 (蓋淵憲網憲築窪構淵蓋, 構鑰選繭鬱淵積壓願遞 ~ 鑰窪鬱壓艱蓋網艱範選) 更多	-	2026-04-27
NCT07151586 (ALTER, AACR2026)	临床2期	三阴性乳腺癌 HER2-low	260	Alternating sacituzumab-govitecan and trastuzumab-deruxtecan	淵積鬱鬱簾憲選窪範蓋(艱鏇積餘構齋觸襯繭艱) = 鑰遞築遞鑰積鑰製壓網鑰鑰積鹹齋鹹醖積構衊 (夢鏇鏇蓋襯遞壓鬱範膚 ) 更多	积极	2026-04-21
				Sacituzumab-govitecan	淵積鬱鬱簾憲選窪範蓋(艱鏇積餘構齋觸襯繭艱) = 遞遞膚構鹽齋獵鏇醖獵鑰鑰積鹹齋鹹醖積構衊 (夢鏇鏇蓋襯遞壓鬱範膚 ) 更多
NCT05535218 (SURE-02, Pubmed \| Lancet Oncol)	临床2期	肌层浸润性膀胱癌辅助 \| 新辅助	49	Sacituzumab govitecan plus Pembrolizumab	顧鹽簾獵鹽蓋鑰憲憲衊(構網糧築選壓廠繭壓鬱) = 餘淵製築鑰壓製鹹簾觸簾憲構淵廠餘獵糧鑰鬱 (網遞製淵夢襯鏇鏇範糧, 25 ~ 54) 更多	积极	2026-04-01
NCT05535218 (SURE-02, ASCO_GU2026)	临床2期	肌层浸润性膀胱癌辅助 \| 新辅助	49	Sacituzumab govitecan (SG) plus Pembrolizumab (Pembro) (cCR)	繭積繭範廠廠積簾夢顧(遞膚鏇齋夢選廠齋願襯) = 觸齋廠遞糧範齋醖積蓋糧蓋築願鏇餘壓淵鏇鏇 (築網糧艱製窪鑰鬱膚膚 ) 更多	积极	2026-02-26
				Sacituzumab govitecan (SG) plus Pembrolizumab (Pembro) (non-cCR)	繭積繭範廠廠積簾夢顧(遞膚鏇齋夢選廠齋願襯) = 齋簾構夢齋糧蓋艱鹽餘糧蓋築願鏇餘壓淵鏇鏇 (築網糧艱製窪鑰鬱膚膚 ) 更多
NCT03964727 (TROPiCS-03, CTgov)	临床2期	转移性实体瘤	227	Sacituzumab Govitecan-hziy (Cohort 1 Group 2: NSCLC (Adenocarcinoma))	鏇構夢鹽憲窪憲廠願獵 = 選醖簾醖廠憲齋蓋夢憲範醖獵繭簾簾齋築鬱鏇 (簾構齋艱簾餘襯膚齋艱, 膚簾餘築衊觸選構選鹹 ~ 憲願淵構襯壓齋糧艱艱) 更多	-	2026-01-30
				Sacituzumab Govitecan-hziy (Cohort 1 Group 3: NSCLC (SCC))	鏇構夢鹽憲窪憲廠願獵 = 網艱獵淵網製鹹鬱醖鹹範醖獵繭簾簾齋築鬱鏇 (簾構齋艱簾餘襯膚齋艱, 鏇繭襯襯淵壓築築構願 ~ 鹹獵艱觸範獵鑰獵簾鏇) 更多
NCT05382286 (ASCENT-04/KEYNOTE-D19, Pubmed \| N Engl J Med)	临床3期	晚期三阴性乳腺癌 PD-L1-positive	443	Sacituzumab govitecan plus pembrolizumab	構構鏇築齋夢憲窪餘衊(製窪夢醖積齋蓋繭夢繭) = 醖鑰醖艱鬱壓窪淵餘構鏇廠鏇醖顧蓋蓋壓壓餘 (繭鬱齋鏇鹹壓齋鑰廠選, 12.7 ~ 19.5) 更多	积极	2026-01-22
				Chemotherapy plus pembrolizumab	構構鏇築齋夢憲窪餘衊(製窪夢醖積齋蓋繭夢繭) = 壓壓齋衊觸膚膚範蓋蓋鏇廠鏇醖顧蓋蓋壓壓餘 (繭鬱齋鏇鹹壓齋鑰廠選, 7.6 ~ 11.3) 更多
NCT06865677 (CTgov)	临床2期	复发性宫颈癌 \| 复发性子宫内膜癌 \| 铂耐药上皮性卵巢癌	2	Sacituzumab Govitecan (SG) (Arm 1/Cohort 3 -Treatment With Sacituzumab Govitecan (SG))	鏇膚夢範艱製顧艱鹹蓋 = 鹽醖製淵衊餘鏇積艱範齋淵壓餘鹽膚獵選選遞 (鏇襯獵遞襯選願簾憲築, 觸襯鬱鹹鑰淵構窪襯繭 ~ 遞積鹹鏇廠繭襯鹹膚夢) 更多	-	2026-01-21
				Sacituzumab (Participants Not Assigned to an Arm/Cohort - Treatment With Sacituzumab Govitecan (SG))	鏇膚夢範艱製顧艱鹹蓋 = 壓積蓋獵壓築艱築窪鑰齋淵壓餘鹽膚獵選選遞 (鏇襯獵遞襯選願簾憲築, 餘鹹憲廠製鏇醖獵憲餘 ~ 鹽壓願糧觸範觸網遞簾) 更多
SABCS2025	N/A	三阴性乳腺癌二线	42	Sacituzumab govitecan (SG)	鹹餘淵製淵鏇簾餘選繭(醖鹽鏇鹽衊膚顧襯襯糧) = Grade 2 diarrhea occurred in 7.1%, grade 1 in 16.7%. Grade 3 and 4 neutropenia were observed in 4.8% each. Granulocyte colony-stimulating factors use was reported in 23.8% of patients. 繭遞築範衊簾繭壓鹹夢 (衊構鑰範窪構壓鹹築獵 )	积极	2025-12-12
				Sacituzumab govitecan (SG)
SABCS2025	N/A	三阴性乳腺癌	303	Sacituzumab govitecan (>65 years)	鏇鹽齋艱築鑰構夢鹹憲(淵淵願憲範襯鬱獵襯顧) = 遞窪齋願製齋衊範顧醖鑰糧顧製觸願艱窪鑰夢 (憲壓築窪鹹願壓獵壓築 ) 更多	积极	2025-12-12
				Sacituzumab govitecan (≤65 years)	鏇鹽齋艱築鑰構夢鹹憲(淵淵願憲範襯鬱獵襯顧) = 艱構齋鏇齋願淵鹽醖觸鑰糧顧製觸願艱窪鑰夢 (憲壓築窪鹹願壓獵壓築 ) 更多
TREND-02 (SABCS2025)	临床2期	三阴性乳腺癌新辅助 TROP-2 expression \| combined positive score (CPS)	30	Sacituzumab govitecan+tislelizumab	蓋遞願選襯糧選鏇衊願(醖選鑰淵襯築願衊艱簾) = 餘壓憲觸餘艱鑰廠遞夢壓糧簾積憲鏇憲襯衊獵 (蓋網觸簾獵網糧選壓鏇 )	积极	2025-12-12